Metronomic 5-Fluorouracil Delivery Primes Skeletal Muscle for Myopathy but Does Not Cause Cachexia
Dean G Campelj, Cara A Timpani, Tabitha Cree, Aaron C Petersen, Alan Hayes, Craig A Goodman, Emma Rybalka
PHARMACEUTICALS | MDPI | Published : 2021
Skeletal myopathy encompasses both atrophy and dysfunction and is a prominent event in cancer and chemotherapy-induced cachexia. Here, we investigate the effects of a chemotherapeutic agent, 5-fluorouracil (5FU), on skeletal muscle mass and function, and whether small-molecule therapeutic candidate, BGP-15, could be protective against the chemotoxic challenge exerted by 5FU. Additionally, we explore the molecular signature of 5FU treatment. Male Balb/c mice received metronomic tri-weekly intraperitoneal delivery of 5FU (23 mg/kg), with and without BGP-15 (15 mg/kg), 6 times in total over a 15 day treatment period. We demonstrated that neither 5FU, nor 5FU combined with BGP-15, affected body ..View full abstract
This study was funded by the former Institute of Sport, Exercise and Active Living, and Centre for Chronic Disease, program grants (both Victoria University).